Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel, affiliated with the Technion, Israel Institute of Technology, Haifa, Israel.
Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel, affiliated with the Technion, Israel Institute of Technology, Haifa, Israel.
Maturitas. 2021 Dec;154:1-6. doi: 10.1016/j.maturitas.2021.09.001. Epub 2021 Sep 6.
Gynecologic Sarcomas are rare, aggressive tumors. The aim of this study was to explore the incidence and outcomes of gynecologic sarcomas in a large national data registry and to compare them with reports from other countries.
Records of gynecologic sarcomas diagnosed in Israel (1980-2014) were extracted from the National Cancer Registry and classified according to International Classification of Diseases for Oncology-3 and characterized according to anatomical site, morphology and demographics. Age-standardized incidence rates and 1, 3, 5 and 10-year relative survival rates were calculated for 3 time periods (1980-1994, 1995-2001 and 2005-2014) according to patient age, stage and years of diagnosis.
During 1980-2014, 1271 new gynecologic sarcomas were diagnosed in Israel, with incidence slightly increasing in 1980-2004, to an age-standardized incidence rate of 13 per million women. The most common histologic diagnosis was leiomyosarcoma (48%) and the most common anatomical site was the uterus (89%). The age-standardized incidence rate for uterine sarcoma is higher in Israel (10.55 per million) than in England (7.4 per million) and Germany (5.8 per million) respectively. The 5-year overall survival was significantly poorer in patients >70-years, as compared to younger patients (p<0.001) and in those with leiomyosarcoma compared to endometrial stromal sarcoma (p<0.001). The survival rate of patients with leiomyosarcoma in Israel are comparable to survival rates reported by other studies, although substantially lower regarding endometrial stromal sarcoma.
Uterine leiomyosarcoma was the most common gynecologic sarcoma found in the Israeli, European and American registries. Older patients and those with leiomyosarcoma have the worst prognoses. Histological and anatomical variations in Israel are comparable with global statistics, but the incidence in Israel seems higher than in Europe.
妇科肉瘤是罕见的侵袭性肿瘤。本研究旨在通过大型国家数据登记处探讨妇科肉瘤的发病率和结局，并与其他国家的报告进行比较。
从国家癌症登记处提取了以色列（1980-2014 年）诊断的妇科肉瘤记录，并根据国际肿瘤学疾病分类-3 进行分类，并根据解剖部位、形态和人口统计学特征进行特征描述。根据患者年龄、分期和诊断年限，计算了 3 个时期（1980-1994 年、1995-2001 年和 2005-2014 年）的年龄标准化发病率和 1、3、5 和 10 年相对生存率。
1980-2014 年期间，以色列共诊断出 1271 例新的妇科肉瘤，发病率在 1980-2004 年略有上升，达到每百万妇女 13 例的年龄标准化发病率。最常见的组织学诊断是平滑肌肉瘤（48%），最常见的解剖部位是子宫（89%）。以色列的子宫肉瘤年龄标准化发病率（每百万 10.55 例）高于英国（每百万 7.4 例）和德国（每百万 5.8 例）。与年轻患者相比（p<0.001），>70 岁的患者和与子宫内膜间质肉瘤相比（p<0.001），5 年总生存率明显较差。以色列平滑肌肉瘤患者的生存率与其他研究报告的生存率相当，尽管子宫内膜间质肉瘤的生存率要低得多。
在以色列、欧洲和美国的登记处，最常见的妇科肉瘤是子宫平滑肌肉瘤。老年患者和患有平滑肌肉瘤的患者预后最差。以色列的组织学和解剖学变化与全球统计数据相当，但发病率似乎高于欧洲。
